ReviewWorld journal of transplantation2016
Post-transplant dyslipidemia: Mechanisms, diagnosis and management.
Review in World journal of transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists.World journal of transplantation · 2026Review
- Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis.Internal medicine (Tokyo, Japan) · 2026Article
- Post-lung transplant surveillance in 2026: current practice, variability, and the need for standardization.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
- Kidney transplantation beyond immunosuppression: shifting the focus from graft survival to patient health.Frontiers in immunology · 2026Review
- Metabolic dysregulation and antibody-mediated rejection after kidney transplantation: interacting mechanisms and emerging clinical strategies.Frontiers in immunology · 2026Review
- The Muscle-Liver Immunometabolic Axis in Liver Transplantation: A Decisive Role in Outcomes and Mechanisms.International journal of biological sciences · 2026Review
- Review
- Framingham risk score is a useful indicator of posttransplant cardiovascular events and survival among Korean kidney transplant recipients: a nationwide, prospective cohort study.Kidney research and clinical practice · 2025Article
- Complications Associated with Immunosuppressive Agents in Solid Organ Transplant Recipients: A Nationwide Analysis.Journal of clinical medicine · 2025Article
- Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults.Current atherosclerosis reports · 2025Review
- Obesity-associated Inflammation and Alloimmunity.Transplantation · 2025Review
- Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk.Current atherosclerosis reports · 2025Review
- Severe Hypertriglyceridemia in a Patient Treated With Sirolimus for Graft-vs-Host Disease Prophylaxis.JCEM case reports · 2024Article
- Review
- Management of kidney transplant recipients for primary care practitioners.BMC nephrology · 2024Review
- Managing dyslipidemia in solid organ transplant patients.Indian heart journal · 2024Review
- Lipid abnormalities in pediatric kidney transplant recipients on steroid withdrawal maintenance immunosuppression.Pediatric nephrology (Berlin, Germany) · 2024Article
- Optimization of Hypercholesterolemia Treatment after Heart Transplant: The Role of PCSK9 Inhibitors.Current pharmaceutical design · 2024Article
- Prevention and Rehabilitation After Heart Transplantation: A Clinical Consensus Statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a Section of ESOT.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Immunosuppressive Agents-Effects on the Cardiovascular System and Selected Metabolic Aspects: A Review.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-transplant dyslipidemia is highly prevalent and presents unique management challenges to the clinician. The two major outcomes to consider with post-transplant therapies for dyslipidemia are preserving or improving allograft function, and reducing cardiovascular risk. Although there are other cardiovascular risk factors such as graft dysfunction, hypertension, and diabetes, attention to dyslipidemia is warranted because interventions for dyslipidemia have an impact on reducing cardiac events in clinical trials specific to the transplant population. Dyslipidemia is not synonymous with hyperlipidemia. Numerous mechanisms exist for the occurrence of post-transplant dyslipidemia, including those mediated by immunosuppressive drug therapy. Statin therapy has received the most attention in all solid organ transplant recipient populations, although the effect of proper dietary advice and adjuvant pharmacological and non-pharmacological agents should not be dismissed. At all stages of treatment appropriate monitoring strategies for side effects should be implemented so that the benefits from these therapies can be achieved. Clinicians have a choice when there is a conflict between various transplant society and lipid society guidelines for therapy and targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.